Domain Therapeutics, a France-based biopharmaceutical company specializing in the research and early development of new drug candidates targeting G protein-coupled receptors (GPCRs), has created a Specific Purpose Vehicle (SPV), Kaldi Pharma, for the exclusive development of its A2a/A1 and A2a antagonist programs.

The mission of Kaldi Pharma is to exploit the patented series of A2a/A1 and A2a antagonists discovered by Domain Therapeutics in any indication in which inhibiting adenosine constitutes a valuable therapeutic approach. It recently has been found that combining an A2a antagonist with immune checkpoint blockers results in enhanced antimetastatic effects.

Kaldi Pharma has granted a worldwide license to Clevexel Pharma for the development of the A2a/A1 preclinical candidate for Parkinson’s disease. CleveXel and Kaldi Pharma signed an agreement for sharing future revenues on the program. Kaldi Pharma is expected to grant a second license for the A2a in oncology to another partner.

After having entrusted the development of a first product to Prexton Therapeutics, with this SPV Domain reaffirms its strategy of moving forward the development of its products up to clinical proof-of-concept through dedicated entities enabling a flexible approach and optimized value creation of its programs.

“For CleveXel, this partnership with Kaldi paves the way for real development of our company. We are very pleased with this license on the innovative molecule for Parkinson’s disease. CleveXel’s expertise in drug development will undoubtedly add value to this program,” said Christian Bloy, president of CleveXel Pharma. “We will make this product a flagship project in our portfolio and take it through to clinical development.”